Skip to content

Released May 11, 2021, after the close

10-Q filed May 11, 2021, 41 days after period end · 0001628280-21-009813

Q1 2021 · 10-Q
Revenue$286.00K— vs Q1 2020+13.9% vs Q4 2020
Net Income-$22.99MN/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.62N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$23,130,000N/M
Operating Cash Flow-$23,147,000N/M
Free Cash Flowderived-$24,941,000N/M
Margins · derived
Operating margin-8087.4%
Net margin-8037.1%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2021Q1 2020
Revenue$286.00K$0.00
Net Income-$22.99M-$13.95M
EPS Diluted-$0.62-$2.71

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR